Logo image of SPRC

SCISPARC LTD (SPRC) Stock Fundamental Analysis

NASDAQ:SPRC - Nasdaq - IL0010951403 - Common Stock

0.5829  +0.04 (+8.06%)

After market: 0.59 +0.01 (+1.22%)

Fundamental Rating

1

Taking everything into account, SPRC scores 1 out of 10 in our fundamental rating. SPRC was compared to 195 industry peers in the Pharmaceuticals industry. SPRC may be in some trouble as it scores bad on both profitability and health. SPRC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SPRC had negative earnings in the past year.
In the past year SPRC has reported a negative cash flow from operations.
SPRC had negative earnings in each of the past 5 years.
SPRC had a negative operating cash flow in each of the past 5 years.
SPRC Yearly Net Income VS EBIT VS OCF VS FCFSPRC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2M -4M -6M -8M -10M

1.2 Ratios

SPRC has a Return On Assets of -46.15%. This is in the lower half of the industry: SPRC underperforms 61.83% of its industry peers.
Looking at the Return On Equity, with a value of -67.77%, SPRC is in line with its industry, outperforming 51.08% of the companies in the same industry.
Industry RankSector Rank
ROA -46.15%
ROE -67.77%
ROIC N/A
ROA(3y)-42.86%
ROA(5y)-136.21%
ROE(3y)-59.52%
ROE(5y)-9664.38%
ROIC(3y)N/A
ROIC(5y)N/A
SPRC Yearly ROA, ROE, ROICSPRC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10K -20K -30K -40K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SPRC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRC Yearly Profit, Operating, Gross MarginsSPRC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

More info and screens

3

2. Health

2.1 Basic Checks

SPRC does not have a ROIC to compare to the WACC, probably because it is not profitable.
SPRC has more shares outstanding than it did 1 year ago.
SPRC has less shares outstanding than it did 5 years ago.
The debt/assets ratio for SPRC is higher compared to a year ago.
SPRC Yearly Shares OutstandingSPRC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
SPRC Yearly Total Debt VS Total AssetsSPRC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

SPRC has an Altman-Z score of -6.72. This is a bad value and indicates that SPRC is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.72, SPRC is doing worse than 69.35% of the companies in the same industry.
SPRC has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
SPRC's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. SPRC outperforms 58.60% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.72
ROIC/WACCN/A
WACC9.17%
SPRC Yearly LT Debt VS Equity VS FCFSPRC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M -10M

2.3 Liquidity

SPRC has a Current Ratio of 4.10. This indicates that SPRC is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.10, SPRC perfoms like the industry average, outperforming 58.60% of the companies in the same industry.
SPRC has a Quick Ratio of 3.63. This indicates that SPRC is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of SPRC (3.63) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.1
Quick Ratio 3.63
SPRC Yearly Current Assets VS Current LiabilitesSPRC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 36.22% over the past year.
SPRC shows a strong growth in Revenue. In the last year, the Revenue has grown by 113.26%.
EPS 1Y (TTM)36.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-163.64%
Revenue 1Y (TTM)113.26%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SPRC Yearly Revenue VS EstimatesSPRC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M 2.5M
SPRC Yearly EPS VS EstimatesSPRC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SPRC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SPRC Price Earnings VS Forward Price EarningsSPRC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRC Per share dataSPRC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SPRC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCISPARC LTD

NASDAQ:SPRC (1/22/2025, 8:00:02 PM)

After market: 0.59 +0.01 (+1.22%)

0.5829

+0.04 (+8.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.33%
Inst Owner Change0%
Ins Owners0%
Ins Owner ChangeN/A
Market Cap6.04M
AnalystsN/A
Price TargetN/A
Short Float %7.68%
Short Ratio0.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.79
P/tB 1.36
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS0
BVpS0.73
TBVpS0.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.15%
ROE -67.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.86%
ROA(5y)-136.21%
ROE(3y)-59.52%
ROE(5y)-9664.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.1
Quick Ratio 3.63
Altman-Z -6.72
F-Score3
WACC9.17%
ROIC/WACCN/A
Cap/Depr(3y)898.83%
Cap/Depr(5y)539.3%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-163.64%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)113.26%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y53.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.67%
OCF growth 3YN/A
OCF growth 5YN/A